Coageight

Coageight  contains the active substance efmoroctocog alfa, a recombinant coagulation factor VIII, Fc fusion protein.

Factor VIII is a protein produced naturally in the body and is necessary for the blood to form clots and stop bleeding. Coageight is a medicine used for the treatment and prevention of bleeding in all age groups of patients with haemophilia A (inherited bleeding disorder caused by factor VIII deficiency).

It is produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) cell line without the addition of any exogenous human- or animal-derived protein in the cell culture process, purification or final formulation.

In patients with haemophilia A, factor VIII is missing or not working properly. Coageight is used to replace the missing or deficient factor VIII. Coageight increases factor VIII level in the blood and temporarily corrects the bleeding tendency.

Coageight is used for:

Haemophilia A (inherited bleeding disorder caused by factor VIII deficiency)